Anyara fails in renal cell cancer but 'potential biomarker' identified
This article was originally published in Scrip
Initial data from Active Biotech's Phase II/III study of its immunotherapy Anyara for the treatment of renal cell cancer (RCC) show that it failed to meet the primary endpoint of overall survival (OS).
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.